Corrigendum: Crystal structure of the GLP-1 receptor bound to a peptide agonist (Nature (2017) 546 (254-258) DOI: 10.1038/nature22800);Crystal structure of the GLP-1 receptor bound to a peptide agonist

Nature

Volumn 546, Issue 7657, 2017, Pages 254-258

  Jazayeri, Ali ^a   Rappas, Mathieu ^a   Brown, Alastair J H ^a   Kean, James ^a   Errey, James C ^a   Robertson, Nathan J ^a   Fiez Vandal, Cédric ^a   Andrews, Stephen P ^a   Congreve, Miles ^a   Bortolato, Andrea ^a   Mason, Jonathan S ^a   Baig, Asma H ^a   Teobald, Iryna ^a   Doré, Andrew S ^a   Weir, Malcolm ^a   Cooke, Robert M ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; PEPTIDE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GLUCAGON RECEPTOR; PEPTIDE;

ANTAGONISM; CHEMICAL BINDING; CRYSTAL STRUCTURE; DIABETES; DISEASE TREATMENT; HOMEOSTASIS; MOLECULAR ANALYSIS; PEPTIDE; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIABETES MELLITUS; DRUG CONFORMATION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; IN VIVO STUDY; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PRIORITY JOURNAL; RAT; AGONISTS; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; HUMAN; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; MALE; MICE; MODELS, MOLECULAR; PEPTIDES; PROTEIN CONFORMATION; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, GLUCAGON;

EID: 85020645798     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23311     Document Type: Erratum

References (47)

1. Todd, J. F. & Bloom, S. R. Incretins and other peptides in the treatment of diabetes. Diabet. Med. 24, 223-232 (2007).
2. Chatterjee, S., Ghosal, S. & Chatterjee, S. Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome. World J. Diabetes 7, 441-448 (2016).
3. Mentlein, R., Gallwitz, B. & Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829-835 (1993).
4. Deacon, C. F., Johnsen, A. H. & Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952-957 (1995).
5. Willard, F. S., Bueno, A. B. & Sloop, K. W. Small molecule drug discovery at the glucagon-like peptide-1 receptor. Exp. Diabetes Res. 2012, 709893 (2012).
6. Mann, R. et al. Peptide binding at the GLP-1 receptor. Biochem. Soc. Trans. 35, 713-716 (2007).
7. Underwood, C. R. et al. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J. Biol. Chem. 285, 723-730 (2010).
8. Runge, S., Thøgersen, H., Madsen, K., Lau, J. & Rudolph, R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J. Biol. Chem. 283, 11340-11347 (2008).
9. Siu, F. Y. et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 499, 444-449 (2013).
10. Jazayeri, A. et al. Extra-helical binding site of a glucagon receptor antagonist. Nature 533, 274-277 (2016).
11. Haque, T. S. et al. Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: homohomophenylalanine analogs. Peptides 31, 950-955 (2010).
12. Haque, T. S. et al. Exploration of structure-activity relationships at the two C-terminal residues of potent 11mer glucagon-like peptide-1 receptor agonist peptides via parallel synthesis. Peptides 31, 1353-1360 (2010).
13. Mapelli, C. et al. Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J. Med. Chem. 52, 7788-7799 (2009).
14. Serrano-Vega, M. J., Magnani, F., Shibata, Y. & Tate, C. G. Conformational thermostabilization of the beta1-adrenergic receptor in a detergent-resistant form. Proc. Natl Acad. Sci. USA 105, 877-882 (2008).
15. Lebon, G. et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474, 521-525 (2011).
16. White, J. F. et al. Structure of the agonist-bound neurotensin receptor. Nature 490, 508-513 (2012).
17. Yang, L. et al. Conformational states of the full-length glucagon receptor. Nat. Commun. 6, 7859 (2015).
18. Hollenstein, K. et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499, 438-443 (2013).
19. Wootten, D., Simms, J., Miller, L. J., Christopoulos, A. & Sexton, P. M. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc. Natl Acad. Sci. USA 110, 5211-5216 (2013).
20. Tom Burnley, B., Afonine, P. V., Adams, P. D. & Gros, P. Modelling dynamics in protein crystal structures by ensemble refinement. eLife 2012, 1-29 (2012).
21. Yang, D. et al. Structural determinants of binding the seven-transmembrane domain of the glucagon-like peptide-1 receptor (GLP-1R). J. Biol. Chem. 291, 12991-13004 (2016).
22. Dods, R. L. & Donnelly, D. The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling. Biosci. Rep. 36, e00285 (2015).
23. Wootten, D. et al. The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism. Cell 165, 1632-1643 (2016).
24. Coopman, K. et al. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor. Mol. Endocrinol. 25, 1804-1818 (2011).
25. Xiao, Q., Jeng, W. & Wheeler, M. B. Characterization of glucagon-like peptide-1 receptor-binding determinants. J. Mol. Endocrinol. 25, 321-335 (2000).
26. Koole, C. et al. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J. Biol. Chem. 287, 3642-3658 (2012).
27. Wood, V. et al. The genome sequence of Schizosaccharomyces pombe. Nature 415, 871-880 (2002).
28. Moon, M. J. et al. Ligand binding pocket formed by evolutionarily conserved residues in the glucagon-like peptide-1 (GLP-1) receptor core domain. J. Biol. Chem. 290, 5696-5706 (2015).
29. López de Maturana, R., Treece-Birch, J., Abidi, F., Findlay, J. B. C. & Donnelly, D. Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. Protein Pept. Lett. 11, 15-22 (2004).
30. Koth, C. M. et al. Molecular basis for negative regulation of the glucagon receptor. Proc. Natl Acad. Sci. USA 109, 14393-14398 (2012).
31. Mason, J. S. et al. High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks. In Silico Pharmacol. 1, 23 (2013).
32. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28, 849-857 (1985).
33. Sciabola, S. et al. High-throughput virtual screening of proteins using GRID molecular interaction fields. J. Chem. Inf. Model. 50, 155-169 (2010).
34. Rasmussen, S. G. F. et al. Crystal structure of the β 2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
35. Deupi, X. & Standfuss, J. Structural insights into agonist-induced activation of G-protein-coupled receptors. Curr. Opin. Struct. Biol. 21, 541-551 (2011).
36. Tehan, B. G., Bortolato, A., Blaney, F. E., Weir, M. P. & Mason, J. S. Unifying family A GPCR theories of activation. Pharmacol. Ther. 143, 51-60 (2014).
37. Wheeler, M. B. et al. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 133, 57-62 (1993).
38. Vilsbøll, T., Agersø, H., Krarup, T. & Holst, J. J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88, 220-224 (2003).
39. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
40. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
41. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
42. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 (2011).
43. Nicholls, R. A., Long, F. & Murshudov, G. N. Low-resolution refinement tools in REFMAC5. Acta Crystallogr. D Biol. Crystallogr. 68, 404-417 (2012).
44. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
45. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
46. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
47. Diederichs. K. & Karplus, P. A. Better models by discarding data? Acta Crystallogr D Biol Crystallogr. 69, 1215-1222 (2013).